Company: XTIA
Filing Date: 2025-06-25
Form Type: 424B4
Source: 0001213900-25-057901
Chunk: 27

Company: XTI Aerospace, Inc.
Filing Date: 2025-06-25
Form: 424B4
Chunk 27
---
 of this Offering. An investor will
not have the opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use the proceeds.
We may use the proceeds of this Offering for purposes with which you do not agree. Moreover, our management may use the net proceeds for
corporate purposes that may not result in our being profitable or increase our market value.

<div align='center'>15

CAPITALIZATION</div>

The following table sets forth
our capitalization as of March 31, 2025 as follows:

| ● | on an actual basis; |

| ● | on a pro forma basis to reflect the following issuances subsequent to March 31, 2025 through June 18, 2025: (i) the issuance of 1,876,000 shares of common stock for an aggregate of $1,876 pursuant to the exercise of 1,876,000 pre-funded warrants that were issued in the March 2025 Offering, (ii) the issuance of 2,769,500 shares of common stock for an aggregate of $3,766,520 pursuant to the exercise of 2,769,500 common warrants that were issued in the March 2025 Offering and (iii) the issuance of 125,000 shares of common stock to ThinkEquity in consideration for financial advisory services pursuant to an advisory agreement dated May 13, 2025; and |

| ● | on a pro forma as adjusted basis to reflect the pro forma adjustments and the issuance and sale by us of (i) 6,231,200 shares of common stock and accompanying Common Warrants to purchase up to 6,231,200 shares of common stock in this offering at a public offering price of $1.75 per share and accompanying Common Warrant, and (ii) Pre-funded Warrants to purchase up to 2,911,800 shares of common stock and Common Warrants to purchase 2,911,800 shares of common stock in this Offering at a public offering price of $1.749 per Pre-funded Warrant and accompanying Common Warrant, assuming no exercise of any Pre-funded Warrants, Common Warrants or Representative’s Warrants and no exercise of the representative’s over-allotment option, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. |

You should read this table
in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included
in the 2024